{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:55:02Z","timestamp":1791006902572,"version":"4.1.0"},"reference-count":18,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.26029","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:14:46Z","timestamp":1790720086000},"page":"248-253","source":"Crossref","is-referenced-by-count":0,"title":["Retained epcoritamab activity despite routine CD20 assay negativity approximately one terminal half-life after mosunetuzumab in B-cell lymphoma"],"prefix":"10.3960","volume":"66","author":[{"given":"Seiji","family":"Kakiuchi","sequence":"first","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naru","family":"Tomigaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimasa","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Harima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kozuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Artificial Intelligence and Digital Health Science, Kobe University Graduate School of Medicine, Kobe, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yodogawa Christian Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023; 141: 467-480.","DOI":"10.1182\/blood.2021011994"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Bartlett NL, Assouline S, Giri P <i>et al.<\/i> Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023; 7: 4926-4935.","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Thieblemont C, Karimi YH, Ghesquieres H <i>et al.<\/i> Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024; 38: 2653-2662.","DOI":"10.1038\/s41375-024-02410-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Jilani I, O\u2019Brien S, Manshuri T <i>et al.<\/i> Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003; 102: 3514-3520.","DOI":"10.1182\/blood-2003-01-0055"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Walsh KJ, Al-Quran SZ, Li Y, Braylan RC, Lynch JW Jr. Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism. Clin Lymphoma Myeloma. 2007; 7: 319-322.","DOI":"10.3816\/CLM.2007.n.010"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Schuster SJ, Huw LY, Bolen CR <i>et al.<\/i> Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas. Blood. 2024; 143: 822-832.","DOI":"10.1182\/blood.2023022348"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Maeshima AM, Taniguchi H, Nomoto J <i>et al.<\/i> Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin\u2019s lymphoma after rituximab therapy. Cancer Sci. 2009; 100: 54-61.","DOI":"10.1111\/j.1349-7006.2008.01005.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Miyoshi H, Arakawa F, Sato K <i>et al.<\/i> Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment. Cancer Sci. 2012; 103: 1567-1573.","DOI":"10.1111\/j.1349-7006.2012.02307.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Salles G, Barrett M, Fo\u00e0 R <i>et al.<\/i> Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017; 34: 2232-2273.","DOI":"10.1007\/s12325-017-0612-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Sun LL, Ellerman D, Mathieu M <i>et al.<\/i> Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7: 287ra70.","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Engelberts PJ, Hiemstra IH, de Jong B <i>et al.<\/i> DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020; 52: 102625.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Thieblemont C, Phillips T, Ghesquieres H <i>et al.<\/i> Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023; 41: 2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Lee DW, Santomasso BD, Locke FL <i>et al.<\/i> ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25: 625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kyvsgaard ER, Grantzau TL, S\u00f8rensen MD <i>et al.<\/i> Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20\u00d7CD3 antibodies. Blood Neoplasia. 2025; 2: 100096.","DOI":"10.1016\/j.bneo.2025.100096"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Bender B, Li CC, Marchand M <i>et al.<\/i> Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Transl Sci. 2024; 17: e13825.","DOI":"10.1111\/cts.13825"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tokunaga T, Tomita A, Sugimoto K <i>et al.<\/i> De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci. 2014; 105: 35-43.","DOI":"10.1111\/cas.12307"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Beers SA, French RR, Chan HT <i>et al.<\/i> Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010; 115: 5191-5201.","DOI":"10.1182\/blood-2010-01-263533"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Klein C, Lammens A, Sch\u00e4fer W <i>et al.<\/i> Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013; 5: 22-33.","DOI":"10.4161\/mabs.22771"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26029\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:45Z","timestamp":1791005685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26029\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.26029","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26029"}}